This article was originally published in The Tan Sheet
Company's non-sedating antihistamine Claritin (loratadine) has been granted six months of pediatric exclusivity, Schering announces Aug. 16. The patent for Claritin was set to expire in June 2002, the company says. The studies Schering submitted in its request for additional marketing exclusivity also are part of supplemental NDAs for Claritin syrup to expand the indications to include children two to five years old. Claritin was discussed as an appropriate switch candidate at an FDA public meeting in June (1"The Tan Sheet" July 3, p. 3)
You may also be interested in...
Switching Rx low- and non-sedating, second-generation antihistamines over-the-counter is unlikely to increase out-of-pocket costs for U.S. consumers based upon OTC pricing of the drugs in foreign countries, a health insurance rep told FDA June 29.
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands